Long-term monitoring of insulin sensitivity in growth hormone-deficient adults on substitutive recombinant human growth hormone therapy

Claudia Giavoli, Silvia Porretti, Cristina L. Ronchi, Vincenzo Cappiello, Emanuele Ferrante, Emanuela Orsi, Maura Arosio, Paolo Beck-Peccoz

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Since the effects of recombinant human growth hormone (rhGH) replacement therapy on glucose metabolism are still a matter of debate, the aim of the present study was to evaluate the impact of long-term rhGH treatment on insulin sensitivity. Simple indices of insulin resistance (IR) and insulin sensitivity (IS), based on fasting glucose and insulin, such as the homeostasis model assessment of insulin resistance (HOMA-IR) and the quantitative insulin check index (QUICKI), were used to estimate the degree of IR and IS in 20 normoglycemic patients (11 men and 9 women; mean age, 44 ± 14 years) with severe adult-onset GH deficiency (GHD). Measurements were determined at baseline and after 1 and 5 years of continuous rhGH therapy. Basal values were compared to those obtained in 20 healthy sex- and age-matched controls. Starting rhGH dose ranged from 3 to 8 μg/kg/d in keeping with sex and age, then doses were titrated according to insulin-like growth factor-I (IGF-I) levels. At baseline all patients had low IGF-I levels (10 ± 5.4 nmol/L), high body mas index (BMI; 27.5 ± 4 kg/m2), and elevated body fat percentage (BF%; 31.8 ± 9.6). Fasting glucose and insulin levels, as well as HOMA-IR and QUICKI, did not differ significantly from those recorded in the control group. After 1 year of rhGH replacement therapy, normalization in IGF-I levels and a significant reduction in BF% were observed (P <.001), and these effects were maintained after 5 years of treatment. Fasting glucose increased from 79 ± 10 to 87 ± 13, and 87 ± 12 mg/dL (P <.05) after 1 and 5 years of therapy, respectively. Fasting insulin significantly increased after 1 year, without further modifications in the long-term follow-up. HOMA-IR significantly increased from 2.1 ± 1.7 to 2.5 ± 1.7 (P <.05) after 1 year, then decreased to 2.3 ± 1.5 (P = not significant [NS] v basal) after 5 years. A specular decrease in QUICKI from 0.37 ± 0.05 to 0.34 ± 0.03 (P <.01) occurred after 1 year, with a trend to increase (0.35 ± 0.04; P = NS v basal) after 5 years. No patient developed impaired fasting glucose. In conclusion, rhGH therapy determined an increase in fasting glucose and insulin levels, causing in the short-term period a worsening of IS. The sustained reduction in BF%, without further deterioration of IS, suggests that long-term beneficial effects on body composition may overcome the negative influence of GH on glucose metabolism.

Original languageEnglish
Pages (from-to)740-743
Number of pages4
JournalMetabolism
Volume53
Issue number6
DOIs
Publication statusPublished - Jun 2004

Fingerprint

Human Growth Hormone
Growth Hormone
Insulin Resistance
Fasting
Insulin
Glucose
Insulin-Like Growth Factor I
Therapeutics
Homeostasis
Hormone Replacement Therapy
Body Composition
Adipose Tissue
Control Groups

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

Long-term monitoring of insulin sensitivity in growth hormone-deficient adults on substitutive recombinant human growth hormone therapy. / Giavoli, Claudia; Porretti, Silvia; Ronchi, Cristina L.; Cappiello, Vincenzo; Ferrante, Emanuele; Orsi, Emanuela; Arosio, Maura; Beck-Peccoz, Paolo.

In: Metabolism, Vol. 53, No. 6, 06.2004, p. 740-743.

Research output: Contribution to journalArticle

Giavoli, Claudia ; Porretti, Silvia ; Ronchi, Cristina L. ; Cappiello, Vincenzo ; Ferrante, Emanuele ; Orsi, Emanuela ; Arosio, Maura ; Beck-Peccoz, Paolo. / Long-term monitoring of insulin sensitivity in growth hormone-deficient adults on substitutive recombinant human growth hormone therapy. In: Metabolism. 2004 ; Vol. 53, No. 6. pp. 740-743.
@article{f0e992c6f6d346dd8cd84c16819c78b5,
title = "Long-term monitoring of insulin sensitivity in growth hormone-deficient adults on substitutive recombinant human growth hormone therapy",
abstract = "Since the effects of recombinant human growth hormone (rhGH) replacement therapy on glucose metabolism are still a matter of debate, the aim of the present study was to evaluate the impact of long-term rhGH treatment on insulin sensitivity. Simple indices of insulin resistance (IR) and insulin sensitivity (IS), based on fasting glucose and insulin, such as the homeostasis model assessment of insulin resistance (HOMA-IR) and the quantitative insulin check index (QUICKI), were used to estimate the degree of IR and IS in 20 normoglycemic patients (11 men and 9 women; mean age, 44 ± 14 years) with severe adult-onset GH deficiency (GHD). Measurements were determined at baseline and after 1 and 5 years of continuous rhGH therapy. Basal values were compared to those obtained in 20 healthy sex- and age-matched controls. Starting rhGH dose ranged from 3 to 8 μg/kg/d in keeping with sex and age, then doses were titrated according to insulin-like growth factor-I (IGF-I) levels. At baseline all patients had low IGF-I levels (10 ± 5.4 nmol/L), high body mas index (BMI; 27.5 ± 4 kg/m2), and elevated body fat percentage (BF{\%}; 31.8 ± 9.6). Fasting glucose and insulin levels, as well as HOMA-IR and QUICKI, did not differ significantly from those recorded in the control group. After 1 year of rhGH replacement therapy, normalization in IGF-I levels and a significant reduction in BF{\%} were observed (P <.001), and these effects were maintained after 5 years of treatment. Fasting glucose increased from 79 ± 10 to 87 ± 13, and 87 ± 12 mg/dL (P <.05) after 1 and 5 years of therapy, respectively. Fasting insulin significantly increased after 1 year, without further modifications in the long-term follow-up. HOMA-IR significantly increased from 2.1 ± 1.7 to 2.5 ± 1.7 (P <.05) after 1 year, then decreased to 2.3 ± 1.5 (P = not significant [NS] v basal) after 5 years. A specular decrease in QUICKI from 0.37 ± 0.05 to 0.34 ± 0.03 (P <.01) occurred after 1 year, with a trend to increase (0.35 ± 0.04; P = NS v basal) after 5 years. No patient developed impaired fasting glucose. In conclusion, rhGH therapy determined an increase in fasting glucose and insulin levels, causing in the short-term period a worsening of IS. The sustained reduction in BF{\%}, without further deterioration of IS, suggests that long-term beneficial effects on body composition may overcome the negative influence of GH on glucose metabolism.",
author = "Claudia Giavoli and Silvia Porretti and Ronchi, {Cristina L.} and Vincenzo Cappiello and Emanuele Ferrante and Emanuela Orsi and Maura Arosio and Paolo Beck-Peccoz",
year = "2004",
month = "6",
doi = "10.1016/j.metabol.2003.11.025",
language = "English",
volume = "53",
pages = "740--743",
journal = "Metabolism: Clinical and Experimental",
issn = "0026-0495",
publisher = "W.B. Saunders Ltd",
number = "6",

}

TY - JOUR

T1 - Long-term monitoring of insulin sensitivity in growth hormone-deficient adults on substitutive recombinant human growth hormone therapy

AU - Giavoli, Claudia

AU - Porretti, Silvia

AU - Ronchi, Cristina L.

AU - Cappiello, Vincenzo

AU - Ferrante, Emanuele

AU - Orsi, Emanuela

AU - Arosio, Maura

AU - Beck-Peccoz, Paolo

PY - 2004/6

Y1 - 2004/6

N2 - Since the effects of recombinant human growth hormone (rhGH) replacement therapy on glucose metabolism are still a matter of debate, the aim of the present study was to evaluate the impact of long-term rhGH treatment on insulin sensitivity. Simple indices of insulin resistance (IR) and insulin sensitivity (IS), based on fasting glucose and insulin, such as the homeostasis model assessment of insulin resistance (HOMA-IR) and the quantitative insulin check index (QUICKI), were used to estimate the degree of IR and IS in 20 normoglycemic patients (11 men and 9 women; mean age, 44 ± 14 years) with severe adult-onset GH deficiency (GHD). Measurements were determined at baseline and after 1 and 5 years of continuous rhGH therapy. Basal values were compared to those obtained in 20 healthy sex- and age-matched controls. Starting rhGH dose ranged from 3 to 8 μg/kg/d in keeping with sex and age, then doses were titrated according to insulin-like growth factor-I (IGF-I) levels. At baseline all patients had low IGF-I levels (10 ± 5.4 nmol/L), high body mas index (BMI; 27.5 ± 4 kg/m2), and elevated body fat percentage (BF%; 31.8 ± 9.6). Fasting glucose and insulin levels, as well as HOMA-IR and QUICKI, did not differ significantly from those recorded in the control group. After 1 year of rhGH replacement therapy, normalization in IGF-I levels and a significant reduction in BF% were observed (P <.001), and these effects were maintained after 5 years of treatment. Fasting glucose increased from 79 ± 10 to 87 ± 13, and 87 ± 12 mg/dL (P <.05) after 1 and 5 years of therapy, respectively. Fasting insulin significantly increased after 1 year, without further modifications in the long-term follow-up. HOMA-IR significantly increased from 2.1 ± 1.7 to 2.5 ± 1.7 (P <.05) after 1 year, then decreased to 2.3 ± 1.5 (P = not significant [NS] v basal) after 5 years. A specular decrease in QUICKI from 0.37 ± 0.05 to 0.34 ± 0.03 (P <.01) occurred after 1 year, with a trend to increase (0.35 ± 0.04; P = NS v basal) after 5 years. No patient developed impaired fasting glucose. In conclusion, rhGH therapy determined an increase in fasting glucose and insulin levels, causing in the short-term period a worsening of IS. The sustained reduction in BF%, without further deterioration of IS, suggests that long-term beneficial effects on body composition may overcome the negative influence of GH on glucose metabolism.

AB - Since the effects of recombinant human growth hormone (rhGH) replacement therapy on glucose metabolism are still a matter of debate, the aim of the present study was to evaluate the impact of long-term rhGH treatment on insulin sensitivity. Simple indices of insulin resistance (IR) and insulin sensitivity (IS), based on fasting glucose and insulin, such as the homeostasis model assessment of insulin resistance (HOMA-IR) and the quantitative insulin check index (QUICKI), were used to estimate the degree of IR and IS in 20 normoglycemic patients (11 men and 9 women; mean age, 44 ± 14 years) with severe adult-onset GH deficiency (GHD). Measurements were determined at baseline and after 1 and 5 years of continuous rhGH therapy. Basal values were compared to those obtained in 20 healthy sex- and age-matched controls. Starting rhGH dose ranged from 3 to 8 μg/kg/d in keeping with sex and age, then doses were titrated according to insulin-like growth factor-I (IGF-I) levels. At baseline all patients had low IGF-I levels (10 ± 5.4 nmol/L), high body mas index (BMI; 27.5 ± 4 kg/m2), and elevated body fat percentage (BF%; 31.8 ± 9.6). Fasting glucose and insulin levels, as well as HOMA-IR and QUICKI, did not differ significantly from those recorded in the control group. After 1 year of rhGH replacement therapy, normalization in IGF-I levels and a significant reduction in BF% were observed (P <.001), and these effects were maintained after 5 years of treatment. Fasting glucose increased from 79 ± 10 to 87 ± 13, and 87 ± 12 mg/dL (P <.05) after 1 and 5 years of therapy, respectively. Fasting insulin significantly increased after 1 year, without further modifications in the long-term follow-up. HOMA-IR significantly increased from 2.1 ± 1.7 to 2.5 ± 1.7 (P <.05) after 1 year, then decreased to 2.3 ± 1.5 (P = not significant [NS] v basal) after 5 years. A specular decrease in QUICKI from 0.37 ± 0.05 to 0.34 ± 0.03 (P <.01) occurred after 1 year, with a trend to increase (0.35 ± 0.04; P = NS v basal) after 5 years. No patient developed impaired fasting glucose. In conclusion, rhGH therapy determined an increase in fasting glucose and insulin levels, causing in the short-term period a worsening of IS. The sustained reduction in BF%, without further deterioration of IS, suggests that long-term beneficial effects on body composition may overcome the negative influence of GH on glucose metabolism.

UR - http://www.scopus.com/inward/record.url?scp=3042854517&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3042854517&partnerID=8YFLogxK

U2 - 10.1016/j.metabol.2003.11.025

DO - 10.1016/j.metabol.2003.11.025

M3 - Article

C2 - 15164321

AN - SCOPUS:3042854517

VL - 53

SP - 740

EP - 743

JO - Metabolism: Clinical and Experimental

JF - Metabolism: Clinical and Experimental

SN - 0026-0495

IS - 6

ER -